Mallory Locklear, Author at żěè¶ĚĘÓƵ Science news and science articles from żěè¶ĚĘÓƵ Wed, 14 Mar 2018 15:46:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 242057827 2018 preview: Opioids will kill tens of thousands more people /article/2156641-2018-preview-opioids-will-kill-tens-of-thousands-more-people/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS Tue, 19 Dec 2017 18:00:00 +0000 http://mg23631574.700 2156641 Focus on liberty and purity may change anti-vax parents’ minds /article/2155356-focus-on-liberty-and-purity-may-change-anti-vax-parents-minds/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2155356-focus-on-liberty-and-purity-may-change-anti-vax-parents-minds/#respond Mon, 04 Dec 2017 16:00:19 +0000 /?post_type=article&p=2155356 A woman protesting a California bills that removes personal belief exemptions for vaccines
Not everyone believes in vaccination
Max Whittaker/New York Times/Redux/eyevine

Vaccines save lives, so why do some parents prefer not to get their children vaccinated against deadly diseases? It seems the ideas of purity and liberty have a big influence.

Avnika Amin at Emory University, Georgia, and her team surveyed more than 1000 adults in the US who had at least one child aged 12 or younger. They assessed the parents’ attitudes towards vaccinations, as well as how much emphasis they put on each of six moral values: authority, fairness, harm, loyalty, purity and liberty. These values are all known to affect judgement and decision-making. “We thought it might be interesting to see if maybe these intuitive values were associated with health decisions,” says Amin.

The team found that 73 per cent of parents got low scores when it was assessed whether they have concerns about vaccinations, but 11 per cent showed some hesitancy around vaccinations, and 16 per cent were highly hesitant.

Compared with those who weren’t very worried, the medium hesitancy parents were twice as likely to place a high emphasis on purity as a moral value. And high hesitancy parents were twice as likely to emphasise purity and liberty, but half as likely to stress authority, compared with low hesitancy parents.

When the team looked at the claims made on anti-vaccination websites, they found that these often appeal to the same moral values.

Appeal to liberty

A better understanding of how moral values affect vaccination attitudes could help public health officials show parents that childhood vaccinations are actually in line with certain values, says Amin.

For example, for those who see liberty as important, a doctor could stress that vaccination is a way to exercise a parent’s freedom in taking control of their child’s health. “We’re not out to change what people value,” says Amin, “but let’s work with those values to show that we’re on the same side.”

“I think the ideas here are really quite novel,” says at the University of California, Riverside. He says we now need to test different types of messaging geared towards these values to see if they can actually change vaccination attitudes.

Nature Human Behaviour

]]>
/article/2155356-focus-on-liberty-and-purity-may-change-anti-vax-parents-minds/feed/ 0 2155356
Brain training game linked to lower dementia risk a decade later /article/2153486-brain-training-game-linked-to-lower-dementia-risk-a-decade-later/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2153486-brain-training-game-linked-to-lower-dementia-risk-a-decade-later/#respond Thu, 16 Nov 2017 14:00:09 +0000 /?post_type=article&p=2153486 An older person doing a crossword
Can certain types of mental activity protect against dementia?
Francisco Martinez / Alamy Stock Photo
Could a computer brain-training program be the first effective tool for preventing dementia? The results from a decade-long study of over a thousand people suggests it might be. Approximately people have dementia worldwide, but there are no known interventions that can be used to reduce the risk of a person developing the condition. Now a study of 2,800 people over the age of 65 has found that those who did a type of brain-training intended to boost a person’s brain processing speed were 29 per cent less likely to develop dementia over a ten-year period. Brain-training is a controversial area. There’s a booming market in computer games designed to improve a person’s memory, attention, or multitasking skills, for example, but evidence on whether they work any better than other types of computer game has been mixed. , of the University of South Florida, and her team have been testing three brain-training programs to see if any might protect against dementia. These programs are designed to target memory, reasoning, or processing speed. “These are very basic abilities that tend to decline with age,” says Edwards.

Processing speed

The participants did one of the three types of training at the start of the study. This consisted ten trials of training, each lasting around 65 minutes, spread across roughly six weeks. The participants were then reassessed by the team at various intervals afterwards, up to ten years later. Only 1,200 people stuck with the study for the full decade. But when the team analysed the data from these people, they found that those who did the speed of processing training were 29 per cent less likely to have developed dementia than people in the control group. Those who did the memory or reasoning training were just as likely to have developed dementia as the control group. The processing training involved having to identify objects briefly displayed on a computer screen. As trials go on, the objects are shown for shorter amounts of time, among other distracting objects, and with increasingly detailed backgrounds, so that the game gets progressively more difficult. Those who received additional training sessions, 11 and 35 months after the first training session, showed even lower rates of dementia. However, it is possible that any improvements seen in the processing speed training group may have been due to chance, and not directly caused by the training itself.

Brief intervention

“I think it’s really interesting,” says , of the Kaiser Permanente Washington Health Research Institute, Seattle. However, he says the results are preliminary and need to be replicated. , of the University of Pittsburgh, agrees. “It warrants further investigation into interventions that are potent enough to slow decline to Alzheimer’s disease or dementia,” she says. There are limitations to the study, including the fact that dementia was determined by self-reporting or cognitive assessments, not a full clinical diagnosis. Some remain skeptical. The findings that only a few hours of cognitive training may reduce dementia risk after ten years should be treated with caution, according to , of University College London. “I find it implausible that such a brief intervention could have this effect,” he said in a statement to the UK Science Media Centre. Journal reference: Alzheimer’s & Dementia: Translational Research & Clinical Interventions Read more: Marathon mind: How brain training could smash world records]]>
/article/2153486-brain-training-game-linked-to-lower-dementia-risk-a-decade-later/feed/ 0 2153486
Grow fake versions of rare delicacies like sea urchin at home /article/2152871-grow-fake-versions-rare-delicacies-like-sea-urchin-home/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2152871-grow-fake-versions-rare-delicacies-like-sea-urchin-home/#respond Fri, 10 Nov 2017 13:54:05 +0000 /?post_type=article&p=2152871
Fisherman opening sea urchins
Soon you can have it without the spikes
REX/Shutterstock

Love sea urchin? Then grow your ownĚýfake version at home. Recently, we’ve seen big research labs growing hamburgers and , but now the Shojinmeat Project in Japan is teaching people how to do it themselves at home.

The project has attracted a wide swathe of people, includingĚýhigh school students culturing sea shells in their refrigerators, and a woman who works at a fish market by day and cultures sea urchin by night. Another group recently grew a small piece of foie gras that they split six ways. “The problem was that none of us were rich enough to know the taste of the real thing,” says Shojinmeat founder Yuki Hanyu. But it certainly wasn’t bad, he says: the foie gras had a lot of umami flavour with a little sweetness. “It definitely tasted like food.”

Culturing meat at home can be more environmentally friendly and doesn’t involve killing an animal. Whether it’s grown in a commercial laboratory or in someone’s home kitchen, culturing meat requires the same basic ingredients:Ěýsome cells from the type of meat you want to grow, an edible structure for them to grow around, and something to nourish them with. The rest is improvisation. The Shojinmeat teamĚýwas surprised to findĚýthat some cells grow well when a portion of their nutrients are provided by sports drinks.

“I think we’re really in an interesting time,” says , a physiology professor at North Carolina State University. The success of the project will depend on how much support is provided, he says.

Shojinmeat have now released instructions on how to build a small bioreactor for culturing meat at home and has also published a cultured meat recipe online. It will probably be a while before cultured meat shows up in our grocery stores, but Shojinmeat is letting people explore that future now. “I would say the dream cultured meat for me would be a nice psoas major steak with exactly the same flavor profile [as the original],” says Mozdziak. “And then after that, we try dinosaur.”

Ěý

Ěý

Ěý

]]>
/article/2152871-grow-fake-versions-rare-delicacies-like-sea-urchin-home/feed/ 0 2152871
Kitchen counter bio-lab lets you make edible gloop from cells /article/2151742-kitchen-counter-bio-lab-lets-you-make-edible-gloop-from-cells/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2151742-kitchen-counter-bio-lab-lets-you-make-edible-gloop-from-cells/#respond Mon, 30 Oct 2017 14:44:39 +0000 /?post_type=article&p=2151742 Cell jam
Could plant-cell bioreactors pave a way forward for food?
VTT Technical Research Centre of Finland Ltd
You might have heard of cultured meat, such as the $300,000 lab-grown burger – but you probably haven’t heard that scientists are trying to do the same for plants. That may sound unnecessary, but as populations grow, available farmland dwindles and climate change takes hold, we’re going to have to find new ways to stabilise our food supply and fortify our diets. That will require new technologies, and in Espoo is leading the charge to make cellular agriculture part of the solution. VTT researcher Lauri Reuter has developed a small bioreactor that looks very much like the kind of pod coffee dispenser you might have on your kitchen counter. The difference is that this machine doesn’t take an espresso forte pod – but cultured plant cells. Just pop in a pod of plant cells along with growth media, and wait for them to turn into jam-like food. They are now at work culturing a range of plant cells, including those taken from the Arctic bramble, strawberries, herbs and birch trees. Cultured cells offer several benefits over the real thing. For a start, our diets are largely made up of just eight crops, yet there are thousands of other plants we could be eating. Many contain important nutritional benefits, but not all are easy to cultivate. Take the Arctic bramble: “A whole plant produces only a single berry,” says Reuter. “It’s not something that you would farm.” This is despite it containing useful nutrients and interesting biomolecules that could benefit our diets. And removed from the context of helping a plant survive, plant cells can suddenly become a lot more productive. “Such a cell line could produce say 10 times, 100 times, 1000 times more of those interesting compounds than the plant out there,” says Reuter.

Dual-purpose

Reuter says the pod bioreactor prototype serves two purposes. Firstly, individuals could be interested in growing their own cells, akin to how some people brew their own beer – but in this case for personalised nutrition. Secondly, it could demystify a concept that will eventually need to become part of the future of food. , a research director at the Institute for the Future in Palo Alto, California, says projects such as Reuter’s could bring about new technologies that help sustain our food supply in the future. Many methods are now being developed, she says, “that help people have access to food that they would like to have access to, stabilise the food supply web, and change the relationship between inputs and outputs”. At this stage, the work is focused on the technology’s development, but the group is looking for a producer that can take the work, scale it up and commercialise it. In addition to kitchen worktops, this type of mechanism might eventually be used to grow cultured plant cells in tailored facilities akin to microbreweries, or even at industrial scales. The team is currently figuring out what each cell type needs to grow and, importantly, how to make them taste good.]]>
/article/2151742-kitchen-counter-bio-lab-lets-you-make-edible-gloop-from-cells/feed/ 0 2151742
Opioid crisis: Trump suggests telling young people drugs are bad /article/2151663-opioid-crisis-trump-suggests-telling-young-people-drugs-are-bad/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2151663-opioid-crisis-trump-suggests-telling-young-people-drugs-are-bad/#respond Fri, 27 Oct 2017 10:41:09 +0000 /?post_type=article&p=2151663
Trump signs memorandum on opioids
Declaring a crisis
NurPhoto/Getty

Back in August, Donald Trump announced that he intended to declare the US opioid crisis – which is killing tens of thousands of people a year – a national emergency. Now he’s done it.

“Effective today, my administration is officially declaring the opioid crisis a national public health emergency under federal law, and why I am directing all executive agencies to use every appropriate emergency authority to fight the opioid crisis,” on 26 October, before signing a presidential memorandum.

The directive calls for increased access to telemedicine in rural areas with doctor shortages, a shuffling of federal funding so more can be applied to the crisis, and some easing of regulations and bureaucratic delays that could otherwise slow down efforts.

However, because the emergency was declared through the Public Health Services Act, it doesn’t automatically come with any additional funding, and President Trump hasn’t yet requested any.

Rather than pushing for emergency aid that could be used to directly help those already suffering from opioid addictions, Trump discussed ways the US could prevent use to begin with.

Advertising effort

The president suggested that targeted advertising campaigns could curtail opioid use. “The fact is, if we can teach young people — and people, generally – not to start, it’s really, really easy not to take them,” he said. “Really tough, really big, really great advertising, so we get to people before they start, so they don’t have to go through the problems of what people are going through.”

He also said that because a significant portion of opioids entering the country come from Latin America, his proposed border wall would boost efforts. “We will be building a wall which will greatly help in this problem,” he said.Ěý“It will have a great impact.”

But the opioid crisis is not only an illegal drug problem – large numbers of people have become addicted to opioids through painkillers prescribed to them by physicians.

Many haveĚýsaid that the lack of additional federal funds will greatly limit what the directive can actually accomplish. In a , Senator Bernie Sanders said, “Trump is right that the opioid crisis is a national emergency. Unfortunately, his announcement today was nothing more than an empty promise.”

Read more: Chronic back pain stem cell treatment could cut need for opioids

]]>
/article/2151663-opioid-crisis-trump-suggests-telling-young-people-drugs-are-bad/feed/ 0 2151663
Marijuana compounds made in GM yeast could help epilepsy /article/2151317-marijuana-compounds-made-in-gm-yeast-could-help-epilepsy/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2151317-marijuana-compounds-made-in-gm-yeast-could-help-epilepsy/#respond Wed, 25 Oct 2017 12:05:28 +0000 /?post_type=article&p=2151317 legal cannabis farm
Grown the old way
Jon Paciaroni/Getty
Cell-sized cannabis factories could soon be producing medical treatments for epilepsy. A non-psychoactive compound found in marijuana plants called cannabidivarin (CBDV) has shown promise in the treatment of severe cases of epilepsy. However, to treat just 10 per cent of people with epilepsy would require around 1500Ěýtonnes of pure CBDV. To obtain this amount using current methods, you would need to plant large quantities of marijuana and extract their small supply of CBDV. “There’s so little of this chemical in plants it would actually be impossible to harvest it by traditional means,” says Kevin Chen, who runs Hyasynth Bio, a start-up in Montreal, Canada. That’s why the firm has turned to cellular agriculture, in which crops are made from cell cultures. It has added the chunk of cannabis DNA that codes for CBDV into yeast DNA, which turns the yeast into CBDV production plants. This allows for rapid, large-scale CBDVĚýcreation with none of the concerns around growing marijuana. “It can be very inefficient to extract these compounds from plants,” says Tom Williams at Macquarie University in Australia, “and that can consume a lot of valuable resources like land and fertiliser.”Ěý TheĚýwork was presented at the NewĚýHarvest conference in New YorkĚýthis month. Once optimised, using microbes likeĚýyeast will make harvesting compounds such as CBDV efficient and cost-effective, says Williams.

Medical applications

The medical applications could be far-reaching. Epilepsy affects around 50 million people worldwide and those diagnosed with it are three times more likely to die prematurely. Around 30 per cent of those with epilepsy don’t respond to available treatments. GW Pharmaceuticals is for epilepsy, andĚýChen says several pharmaceutical companies have been in touch with Hyasynth Bio. But CBDV is just one of dozens of cannabinoids in the cannabis plant. If more medical applications are discovered for these, yeast-based production could rapidly generate them. “Many or all plant natural products used in the pharmaceutical industry will ultimately be produced by this technology,” says Kristy Hawkins, a founder of San-Francisco yeast biomanufacturer Antheia. “It is just a matter of time.” Not to mention the plant’s most common use. Chen told the that Hyasynth Bio is also open to moving into the recreational marijuana field. And as Canada is poised to become the second country in the world to legalise marijuana use nationwide, there could be a fair amount of demand for yeast-produced THC. “I’m happy to be ending the conference on a high note,” said Chen.]]>
/article/2151317-marijuana-compounds-made-in-gm-yeast-could-help-epilepsy/feed/ 0 2151317
Side effects are worse when we think medication looks expensive /article/2149552-side-effects-are-worse-when-we-think-medication-looks-expensive/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2149552-side-effects-are-worse-when-we-think-medication-looks-expensive/#respond Thu, 05 Oct 2017 18:00:07 +0000 /?post_type=article&p=2149552
A person with skin cream
How fancy was the packaging?
Photodsotiroff/Getty

Watch the cost. People are more likely to experience stronger side effects when a treatmentĚýappears to be more expensive, according to a study of the nocebo effect.

While the placebo effect means that some people feel better when they have unknowingly been given a sham or control treatment, the nocebo works the opposite way. Researchers frequently observe nocebo effects in clinical trials, when people who receive a placebo experience negative side effects as if they had been given an actual drug.

Placebos are known to have stronger positive effects the more expensive the person receiving them believes them to be. , at the University Medical Center Hamburg-Eppendorf, and her colleagues wondered if price might also affect the strength of the nocebo effect.

The team created two packages for fake creams and told volunteers that they are used to treat itchy skin. One package looked like an expensive pharmaceutical brand name, while the other looked like a cheaper, generic medication.

The participants were shown one of the two creams and told that it was believed to increase a person’s sensitivity to pain as a side effect.

Pain sensitivity

The team then applied creams to participants’ arms, and exposed their limbs to increasing levels of heat. Each person was asked to rank the discomfort they felt.

The participants given the more expensive-looking cream reported more pain than those given the cheaper-looking cream. Relative to a control cream that was described as having no active ingredients, the generic-looking cream raised pain on average by around 3 per cent, while the expensive-looking cream increased pain by nearly 30 per cent.

The finding confirms that the price of a treatment effects not only placebo strength, but nocebo power too.

During the pain test, the team collected fMRI images of the brain, brainstem and spinal cord. They found that activity in a particular area of the prefrontal cortex and a region called the periaqueductal gray varied depending on what cream had been given. Both these areas are part of the neural pain pathway, and have also been implicated in mediating placebo effects.

The findings may help refine how doctors nurses and pharmacists talk to patients about medications, enabling them to try to minimize the nocebo effect, says Tinnermann.

Journal reference: Science, DOI: 10.1126/science.aan1221

Read more: Tap the placebo effect to unlock your body’s healing powers

]]>
/article/2149552-side-effects-are-worse-when-we-think-medication-looks-expensive/feed/ 0 2149552
Pioneering gene therapy approved for leukaemia in the US /article/2146048-pioneering-gene-therapy-approved-for-leukaemia-in-the-us/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2146048-pioneering-gene-therapy-approved-for-leukaemia-in-the-us/#respond Fri, 01 Sep 2017 10:10:43 +0000 /?post_type=article&p=2146048 CAR-T therapy Kymriah
Carrying a $475,000 price-tag
AP
A CAR-T treatment – a type of gene therapy for cancer – has been approved for use in the US. Announced by the US Food and Drug Administration (FDA) on Wednesday, this is the first approval anywhere in the world for a type of CAR-T therapy, although the techniques have been used experimentally for some time. CAR-T therapy made headlines earlier this year, when it was announced a CAR-T approach had saved the life of Layla, a young child in the UK who had leukaemia. The approach involves reprogramming a person’s own immune cells to make them better at targeting cancerous ones. The drug that has been approved by the FDA is Kymriah, a treatment for B-cell acute lymphoblastic leukaemia, the most common childhood cancer in the US. To synthesise Kymriah, a patient first has a type of immune cell, called T-cells, removed from their body and transported to a facility in New Jersey operated by the pharmaceutical firm Novartis. Here, viruses will be used to insert a gene into these cells. The gene codes for a protein called a chimeric antigen receptor (CAR). These cells are then reinfused back into the person. The added protein helps these modified T-cells home in on and fight leukemia cells. In a trial, this approach achieved an 83 per cent remission rate over a period of three months in people who hadn’t responded to other treatment options. The FDA has approved Kymriah for people aged 25 or under who have not responded to other treatments, or who have relapsed.

One-off treatment

Nearly half the people in the trial experienced a side effect caused by an unwanted immune response triggered by the altered T-cells. Because of this, the FDA is requiring staff at the 32 facilities approved for this treatment to undergo specific training to recognise this response, called cytokine release syndrome. Kymriah will cost $475,000. This sounds high, but it’s lower than some analysts expected, and unlike many expensive cancer drugs, it is a one-off treatment that could result in years, not months, of extended lifespan. The FDA’s decision has been hailed as the first approval for a gene therapy in the US. Some argue that this isn’t a true gene therapy, as the genes introduced into the T-cells are not the treatment themselves – it is the transformed T-cells that go on to fight the cancer. But the FDA defines human gene therapy as products that introduce genetic material into a person’s DNA to treat a disease, so has classified Kymriah as such. Europe has already two gene therapies for inherited diseases, while China a gene therapy for cancer treatment in 2004. As for CAR-T therapies, other firms have similar treatments in the works, while Novartis also plans to get Kymriah approved for treating lymphoma.]]>
/article/2146048-pioneering-gene-therapy-approved-for-leukaemia-in-the-us/feed/ 0 2146048
Immigrant protections have halved kids’ mental health problems /article/2145955-immigrant-protections-have-halved-kids-mental-health-problems/?utm_campaign=RSS|NSNS&utm_content=currents&utm_medium=RSS&utm_source=NSNS /article/2145955-immigrant-protections-have-halved-kids-mental-health-problems/#respond Thu, 31 Aug 2017 18:00:40 +0000 /?post_type=article&p=2145955
DACA
People rally in a bid to save the DACA immigrant protection programme
Albin Lohr-Jones/Pacific Press/LightRocket via Getty Images

US legislation that protects some immigrants from deportation has been good for the mental health of their children. But the programme is under threat, with president Donald Trump expected to announce whether he will scrap it next week.

The Deferred Action for Childhood Arrivals (DACA) programme was introduced by president Barack Obama in 2012. It provides undocumented immigrants who had arrived in the US before 2007 as children with work permits and protection from deportation.

To investigate how immigration status can affect a person’s family, at Stanford University and his colleagues have been using data from Oregon’s Emergency Medicaid programme, a healthcare scheme predominantly used by undocumented immigrants.

The researchers analysed data linked to more than 5600 mothers who used Emergency Medicaid between 2003 and 2015, splitting them into two groups – those whose birthdates made them eligible for DACA protections, and those born just before the June 1981 cut-off. They then analysed mental health diagnoses across the women’s 8610 children, who are all US citizens by birth.

Dramatic drop

The team found that 7.8 per cent of children whose mothers were not eligible for DACA were diagnosed during the study period with adjustment or anxiety disorders – mental health issues often affected by external stresses, such as the threat of a parent being deported.

But only 3.3 per cent of children with mothers eligible for DACA protections were diagnosed with the same disorders.

“The fact that it reduced by over 50 per cent is really astonishing,” says at Montclair State University in New Jersey. “It shows that this policy can have huge impacts on the life of an entire family.”

Hainmueller says that his team was surprised by the large drop in diagnoses. “I think this is the clearest causal evidence we have that this undocumented status of the parents can really be a significant barrier to the normal development of the children,” he says.

The team is now doing similar analyses with data from other states, including California and New York. But DACA’s days may be numbered. Trump was critical of the programme during his election campaign last year, and has until 5 September to decide whether he will dissolve it.

Journal reference: Science, DOI:

Read more: The truth about migration

]]>
/article/2145955-immigrant-protections-have-halved-kids-mental-health-problems/feed/ 0 2145955